Assertio Therapeutics Inc
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
- Ticker
- ASRT
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mark L. Reisenauer
- Headquarters
- 100 South Saunders Road, Lake Forest, IL, United States, 60045
- Employees
- 53
- Website
- assertiotx.com
Metrics
Analyst Insights & forecasts
Based on information from 4 analysts.
Earnings per share (EPS) forecast
| Q2 • 25 | Q3 • 25 | Q4 • 25 | |
|---|---|---|---|
| Actual | $0.30 | $2.70 | -$1.06 |
| Expected | -$0.07 | -$0.09 | -$0.07 |
| Surprise | 528.57% | 3,100.00% | -1,530.77% |
| Beat | Beat | Current |
Financial Performance
| Q4 • 25 | Q1 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $13.5M | $9.9M | -26.65% |
| Net income | $-11.9M | $-18.9M | 58.08% |
| Profit margin | -88.08% | -189.83% | 115.52% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Assertio Therapeutics Inc share?
Assertio Therapeutics Inc shares are currently traded for undefined per share.
02How many shares does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc currently has 6.5M shares.
03Does Assertio Therapeutics Inc pay dividends?
No, Assertio Therapeutics Inc doesn't pay dividends.
04What is Assertio Therapeutics Inc 52 week high?
Assertio Therapeutics Inc 52 week high is $28.55.
05What is Assertio Therapeutics Inc 52 week low?
Assertio Therapeutics Inc 52 week low is $8.72.
06What is the 200-day moving average of Assertio Therapeutics Inc?
Assertio Therapeutics Inc 200-day moving average is $14.90.
07Who is Assertio Therapeutics Inc CEO?
The CEO of Assertio Therapeutics Inc is Mark L. Reisenauer.
08How many employees Assertio Therapeutics Inc has?
Assertio Therapeutics Inc has 53 employees.
09What is the market cap of Assertio Therapeutics Inc?
The market cap of Assertio Therapeutics Inc is $152M.
10What is the P/E of Assertio Therapeutics Inc?
The current P/E of Assertio Therapeutics Inc is null.
11What is the EPS of Assertio Therapeutics Inc?
The EPS of Assertio Therapeutics Inc is -$5.55.
12What is the PEG Ratio of Assertio Therapeutics Inc?
The PEG Ratio of Assertio Therapeutics Inc is 1.5.
13What do analysts say about Assertio Therapeutics Inc?
According to the analysts Assertio Therapeutics Inc is considered a buy.


